What is William Blair's Forecast for Exagen FY2025 Earnings?

Key Points

• William Blair has revised its FY2025 earnings estimates for Exagen Inc., lowering the forecast from ($0.61) to ($0.62) per share, with a consensus estimate at ($0.88) per share.
• Exagen reported ($0.18) EPS for the most recent quarter, aligning with analyst expectations, while revenue reached $17.20 million, exceeding estimates of $16.25 million.
• Despite the negative outlook on earnings, several analysts maintain a "buy" rating on Exagen, with price targets ranging from $10.00 to $12.00 per share.

Exagen Inc. (NASDAQ:XGN - Free Report) - Investment analysts at William Blair cut their FY2025 earnings estimates for shares of Exagen in a research report issued on Wednesday, July 30th. William Blair analyst A. Brackmann now anticipates that the company will post earnings of ($0.62) per share for the year, down from their prior forecast of ($0.61). The consensus estimate for Exagen's current full-year earnings is ($0.88) per share. William Blair also issued estimates for Exagen's Q4 2025 earnings at ($0.11) EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.34) EPS.

Exagen (NASDAQ:XGN - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($0.18) EPS for the quarter, hitting analysts' consensus estimates of ($0.18). Exagen had a negative net margin of 28.85% and a negative return on equity of 130.38%. The firm had revenue of $17.20 million for the quarter, compared to analyst estimates of $16.25 million.

XGN has been the topic of a number of other research reports. Cantor Fitzgerald restated an "overweight" rating and issued a $10.00 target price on shares of Exagen in a research note on Wednesday, July 30th. BTIG Research restated a "buy" rating on shares of Exagen in a research note on Wednesday, May 7th. UBS Group restated an "overweight" rating on shares of Exagen in a research note on Thursday, May 15th. KeyCorp raised shares of Exagen from a "sector weight" rating to an "overweight" rating and set a $12.00 price objective for the company in a research report on Wednesday, July 30th. Finally, Craig Hallum began coverage on shares of Exagen in a research report on Wednesday, July 23rd. They set a "buy" rating and a $12.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $11.25.

Exagen Stock Down 0.6%

Shares of Exagen stock traded down $0.05 during trading on Friday, reaching $8.80. The company had a trading volume of 121,022 shares, compared to its average volume of 230,884. The company has a market cap of $193.60 million, a price-to-earnings ratio of -9.89 and a beta of 1.61. The firm's fifty day moving average is $7.24 and its 200-day moving average is $5.49. The company has a debt-to-equity ratio of 1.06, a quick ratio of 4.95 and a current ratio of 4.95. Exagen has a fifty-two week low of $2.24 and a fifty-two week high of $9.10.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC bought a new position in shares of Exagen in the first quarter valued at approximately $25,000. Corient Private Wealth LLC acquired a new stake in Exagen during the fourth quarter valued at approximately $45,000. Marshall Wace LLP acquired a new stake in Exagen during the fourth quarter valued at approximately $66,000. Northern Trust Corp lifted its stake in Exagen by 16.7% during the fourth quarter. Northern Trust Corp now owns 18,375 shares of the company's stock valued at $75,000 after purchasing an additional 2,630 shares during the last quarter. Finally, Huntleigh Advisors Inc. lifted its stake in Exagen by 16.8% during the first quarter. Huntleigh Advisors Inc. now owns 83,108 shares of the company's stock valued at $298,000 after purchasing an additional 11,939 shares during the last quarter. Institutional investors own 75.25% of the company's stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).